Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: BLUE HORSE SHOE who wrote (356)	4/6/1998 2:39:00 PM
From: Manny Gugliuzza	Read Replies (1) \| Respond to of 1510

good to hear your comments blue especially comming from a large holder that has been in as long as myself. whew 105 pages that WAS well prepared but i did not find that much difference to associate stock weakness too, except for the part 14 under business. but very direct and encouraging in the business marketing aspect they are preparing for now. it seems not a matter of if but when FDA approval will come. well after a near perfect test of the head and shoulder at 9.5 time to see if 11 will produce more sell off. very encouraged by the short time spent under 50 day MA which it keeps flirting with. ar.

To: BLUE HORSE SHOE who wrote (356)	4/6/1998 5:14:00 PM
From: Easy Mark	Respond to of 1510

Top ten reasons to short IMNR: 1. IRC insiders tend to sell at the peak as they did in 1992 and late 1997. 2. There is no clinical data showing efficacy of Remune. 3. IRC has only 6 months of cash left. 4. Cell Genesys has a competing t-cell technology with greater flexibility than IRC's 5. IRC has history of trying to hype its technology. 6. Insiders have structured their deals to cash out in relatively short period. 7. The rest of IRC's pipeline is at least a year away from beginning Phase III. 8. At least two alternate therapeutic vaccines are in development that compete against Remune. 9. In 1994, FDA did not accept company's claims as credible. 10. Overwhelming clinical efficacy of drug therapies may reduce interest in therapeutic vaccines.